Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Neurologic Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Neurologic Other
    Growth Hormone IGF-1 Not Beneficial for ALS - (DGNews)
    Phenytoin, Fosphenytoin May Increase Risk of Serious Skin Reactions in Asian Patients With HLA-B*1502 Allele - (DGNews)
    Ginkgo Evaluation of Memory Study Fails to Show Benefit in Preventing Dementia in the Elderly - (DGNews)
    Routine Testing After Aneurysm Coiling Carries Low Risk - (DGNews)
    FDA Approves Rufinamide as Adjunctive Treatment for Lennox-Gastaut Syndrome - (DGNews)

    News archive

     Recent webcasts/CME - Neurologic Other
    Role of the Autonomic Nervous System in Atrial Fibrillation
    Delirium in the ICU: An Overview

    Webcasts/CME archive

     Recent cases - Neurologic Other
      Hyperkalaemic Paralysis Presenting as ST-Elevation Myocardial Infarction: A Case Report
      Free Functional Gracilis Muscle Transfer in Children with Severe Sequelae from Obstetric Brachial Plexus Palsy
      Adalimumab Induced Mononeuritis Multiplex in a Patient with Refractory Rheumatoid Arthritis: A Case Report
      IgM Multiple Myeloma Presenting with Spinal Cord Compression Caused by a Plasmacytoma: A Case Report
      Postpartum Thunderclap Headache

      Cases archive
        




      my personal edition > neurologic other > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Pergolide Appears Safe and Effective in Patients with Tourette's Syndrome: Presented at ANA

      By Thomas S. May
      Special to DG News

      NEW YORK, NY -- October 16, 2002 -- Pergolide, a mixed C1/D2/D3 dopamine agonist, appears to be safe and effective in the treatment of children and adolescents with Tourette's syndrome, new research suggests.

      Dr. Donald Gilbert, director of the Tourette's Syndrome and Movement Disorders Clinics in Cincinnati, Ohio, United States, presented the findings here October 15 at the 127th annual meeting of the American Neurological Association (ANA).

      Neuroleptics, which block dopamine transmission, are currently used for the treatment of children with severe tics, but major side effects and limited efficacy reduce their clinical utility. Results of prior open-label and crossover studies of pergolide have indicated that it may suppress tics.

      In an attempt to investigate this possibility, Dr. Gilbert and colleagues enrolled 56 children, aged 7 to 17 years, who had been diagnosed with Tourette's syndrome, in a randomised, double-blind, placebo-controlled trial. Patients were given 0.15-0.45 mg pergolide daily or placebo during the eight-week study. Tic severity was assessed by the Yale Global Tic Severity Scale (YGTSS).

      Compared with placebo treatment, pergolide treatment was associated with significantly greater tic reduction (pergolide vs. placebo treatment effect = 8.8 units; p=0.05). No serious adverse events occurred in any of the patients, and pergolide was well tolerated.

      "This trial is the largest study of dopamine agonists for tic reduction, and the results show a statistically significant, mild to moderate tic reduction, as well as significant improvement in attention deficit hyperactive disorder symptoms," Dr. Gilbert said.

      "The greatest benefit tended to occur in the younger children," he added.

      Medications currently used for tic suppression tend to have modest benefit, and in some cases, undesirable side effects, according to Dr. Gilbert. "If clonidine and guanfacine are not effective, pergolide may be a reasonable choice prior to trying a neuroleptic medication," he suggested.

      The study was funded by a grant from the United States' Food and Drug Administration (FDA).



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send